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Summary
Background Some studies, mainly from high-income countries (HICs), report that women receive less care 
(investigations and treatments) for cardiovascular disease than do men and might have a higher risk of death. 
However, very few studies systematically report risk factors, use of primary or secondary prevention medications, 
incidence of cardiovascular disease, or death in populations drawn from the community. Given that most 
cardiovascular disease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive 
information comparing treatments and outcomes between women and men in HICs, middle-income countries, and 
low-income countries from community-based population studies.
Methods In the Prospective Urban Rural Epidemiological study (PURE), individuals aged 35–70 years from urban 
and rural communities in 27 countries were considered for inclusion. We recorded information on participants’ 
sociodemographic characteristics, risk factors, medication use, cardiac investigations, and interventions. 
168 490 participants who enrolled in the first two of the three phases of PURE were followed up prospectively for 
incident cardiovascular disease and death.
Findings From Jan 6, 2005 to May 6, 2019, 202 072 individuals were recruited to the study. The mean age of women 
included in the study was 50·8 (SD 9·9) years compared with 51·7 (10) years for men. Participants were followed up 
for a median of 9·5 (IQR 8·5–10·9) years. Women had a lower cardiovascular disease risk factor burden using two 
different risk scores (INTERHEART and Framingham). Primary prevention strategies, such as adoption of several 
healthy lifestyle behaviours and use of proven medicines, were more frequent in women than men. Incidence of 
cardiovascular disease (4·1 [95% CI 4·0–4·2] for women vs 6·4 [6·2–6·6] for men per 1000 person-years; adjusted 
hazard ratio [aHR] 0·75 [95% CI 0·72–0·79]) and all-cause death (4·5 [95% CI 4·4–4·7] for women vs 7·4 [7·2–7·7] 
for men per 1000 person-years; aHR 0·62 [95% CI 0·60–0·65]) were also lower in women. By contrast, secondary 
prevention treatments, cardiac investigations, and coronary revascularisation were less frequent in women than men 
with coronary artery disease in all groups of countries. Despite this, women had lower risk of recurrent cardiovascular 
disease events (20·0 [95% CI 18·2–21·7] versus 27·7 [95% CI 25·6–29·8] per 1000 person-years in men, adjusted 
hazard ratio 0·73 [95% CI 0·64-0·83]) and women had lower 30-day mortality after a new cardiovascular disease event 
compared with men (22% in women versus 28% in men; p<0·0001). Differences between women and men in 
treatments and outcomes were more marked in LMICs with little differences in HICs in those with or without 
previous cardiovascular disease.
Interpretation Treatments for cardiovascular disease are more common in women than men in primary prevention, 
but the reverse is seen in secondary prevention. However, consistently better outcomes are observed in women than 
in men, both in those with and without previous cardiovascular disease. Improving cardiovascular disease prevention 
and treatment, especially in LMICs, should be vigorously pursued in both women and men.
Funding Full funding sources are listed at the end of the paper (see Acknowledgments).
Copyright © 2020 Elsevier Ltd. All righst reserved.
Introduction
Over the past two decades, substantial efforts have been 
made to improve the cardiovascular health of women 
under the assumption that women with cardiovascular 
disease are managed less aggres sively than men. Several 
campaigns, coalitions, and programmes1,2 have been 
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initiated to improve awareness, advocacy, and research 
related to reducing the cardio vascular disease burden and 
to implement delivery care models and guidelines3,4 that 
are specific to women. Despite these efforts, reported 
differences in the cardio vascular disease burden, manage­
ment, and outcomes between women and men remain. 
Although some studies report that women have lower age­
standardised cardiovascular disease incidence, prevalence, 
and death rates than men,5,6 there are also reports that 
women with cardiovascular disease receive less care,7–9 
fewer investigations,7–9 and have poorer outcomes9,10 after 
a coronary event. These reports have led to renewed calls 
for intensified efforts to improve care for women.1,2,11 
To date, a comprehensive report of cardiovascular dis­
ease risk factor burden, management, and outcomes 
in women and men with and without a history of 
cardiovascular disease drawn from a community­based 
population sample is not available. Such community­
based studies are crucial because hospital registries, 
data from outpatient clinics, and administrative databases 
do not provide information on primary prevention 
strategies nor do they include information regarding 
cardiovas cular events and deaths before hospitalisation. 
Moreover, studies on cardiovascular disease differences 
between women and men are mainly from high­income 
countries (HICs)—largely from North America and 
western Europe—with little data from other regions or 
low­income and middle­income countries (LMICs). 
Because the majority of cardiovascular disease deaths now 
occur in LMICs,12 it is important to examine the differences 
between women and men regarding disease prevention, 
treatment, incidence, and related deaths globally.
The aims of this Article are to describe differences 
between women and men from all countries and sepa rately 
in those from HICs, middle­income countries (MICs), and 
low­income countries (LICs). Moreover, women and men 
will be compared by regions with regard to the burden of 
cardiovascular disease risk factors; the incidence of major 
cardiovascular disease (cardiovascular deaths, myocardial 
infarction, strokes, heart failure, and other major cardio­
vascular disease events) and all­cause death; case­fatality 
rates after an incident cardiovascular disease event; the use 
of preventive medicines, risk factor control, and healthy 
lifestyle behaviours in those with and without a history of 
cardiovascular disease; and differences in the rates of 
cardiac inves tigations, revascularisation procedures, and 
recurrent cardiovascular disease events in those with 
coronary artery disease over the 9·5 year follow­up.
Research in context
Evidence before this study
We searched the MEDLINE database, without language or 
publication date restrictions, for estimates of differences between 
women and men in cardiovascular disease risk factors, incidence, 
deaths, and use of treatments on Sept 15, 2019, and again on 
Nov 30, 2019. Our search terms were “gender” OR “sex” OR 
“women” AND “cardiovascular” OR “coronary heart disease” OR 
“coronary artery disease” OR “risk factor” OR “revascularization” 
OR “percutaneous coronary intervention” OR “coronary artery 
bypass grafting” OR “primary prevention” OR “statin” OR 
“secondary prevention”.
Studies have emphasised that women are less likely to undergo 
revascularisation procedures and receive fewer guideline 
recommended therapies than men upon having a cardiovascular 
disease event. These findings, when viewed in isolation, 
have raised concerns that women are disadvantaged when it 
comes to cardiovascular disease care. However, much of the 
existing evidence was from North America and Europe, and 
most of the published literature are based on hospital registries, 
outpatient clinics, or administrative databases. We did not find 
any comprehensive report on differences between women and 
men in risk factors, management, and outcomes in those with 
and without a history of cardiovascular disease drawn from 
community-based populations.
Added value of this study
We systematically examine differences in risk factors, 
treatments, cardiovascular disease incidence, and mortality in 
a large population with and without previous cardiovascular 
disease between women and men from high-income, middle-
income, and low-income countries. Our findings indicate that 
the cardiovascular disease risk factor burden is lower in women; 
this is consistent across countries at all economic levels and 
geographical regions. Moreover, primary prevention strategies 
are used more frequently in women than in men, and are 
accompanied by lower incidence of cardiovascular disease and 
mortality. By contrast, use of secondary prevention treatments, 
cardiac investigations, and coronary interventions, are less 
frequent in women than in men, but are not associated with a 
higher rate of recurrent cardiovascular disease or death in 
women over a median follow-up time of 9·5 (IQR 8·5–10·9) 
years. The differences in treatments and in outcomes in both 
women and men from low-income and middle-income 
countries compared with high-income countries are much 
larger than the differences between sexes globally or within 
groups of countries.
Implications of all the available evidence
Although there are contrasting patterns in the differences in 
treatment rates between women and men in those with and 
without previous cardiovascular disease, our data indicate that 
women do not have worse cardiovascular disease outcomes 
compared with men. The differences in cardiovascular disease 
incidence, death, and use of treatments in both women and 
men between high-income compared with low-income and 
middle-income countries, and North America and Europe versus 
other regions is much larger. Understanding and narrowing 
these gaps deserve greater attention.
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Methods
Study design and participants
The Prospective Urban Rural Epidemiological (PURE) 
study is a large international prospective cohort study 
of 202 072 women and men aged 35–70 years from 
1030 communities living in 27 HICs, MICs, and LICs, 
across six geographical regions: Asia, Africa, Europe, 
South America, North America, and the Middle East. 
The inclusion and exclusion criteria remained the same 
as previous PURE Articles.13
Details of the study design, sampling, and recruitment 
have been previously published and are also described 
in the appendix (pp 7–12).13 Briefly, participants were 
enrolled in three phases, which began in 2003. In phase 
one, 157 705 participants were recruited from 17 countries, 
with 10 785 partici pants recruited in phase two from 
an additional four countries, and 9321 participants 
recruited in phase three from four more countries. Data 
from two ongoing cohorts from South America were also 
included (n=24 261) in phase three. The participating 
countries and communities were selected with the aim 
of obtaining a socioeconomically diverse study sample 
while also ensuring feasibility of long­term follow­up. 
Households within communities were selected to be 
broadly repre sentative of the socio demographic composi­
tion of the communities they live in. We have previously 
shown that the characteristics and death rates of the 
enrolled participants were similar to their national 
populations.14
The study was coordinated by the Population Health 
Research Institute, Hamilton Health Sciences and 
McMaster University, Hamilton, ON, Canada. Ethics 
committees at each participating centre approved the 
protocol and all participants provided informed written 
consent.13
Procedures
Standardised methods were used to collect information on 
cardiovascular disease risk factors.13 Blood samples were 
drawn from each participant at baseline data collection 
and centrally analysed using validated and standardised 
methods analysed at Population Health Research Institute, 
Hamilton Health Sciences, Hamilton, ON, Canada. Medi­
cines taken by the participant at least once per week in the 
month before enrolment onto the study were recorded by 
direct inspection of medicines or prescriptions.
Follow­up occurred at least every 3 years, during which 
information on clinical events (major cardiovascular 
disease, myocardial infarction, stroke, heart failure, and 
all­cause death) was obtained from participants or family 
members of deceased participants. Follow­up data are 
currently available for 168 490 participants from phase one 
and two, with ongoing follow­up in all other participants. 
Events were adjudicated in each country using stan­
dardised definitions, verbal autopsies,15 and review of 
additional documents (eg, medical records, and hospital 
or physician reports).13 In this Article, we report on 
follow­up event data available until July 5, 2019, and the 
median follow­up time was 9·5 (IQR 8·5–10·9) years.
We summarised the overall risk­factor burden using the 
previously validated non­laboratory based INTERHEART16,17 
and the Framingham18 risk scores. We documented the use 
of antiplatelet drugs, β blockers, angiotensin converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers, 
statins, hyper tension control, and adoption of healthy 
lifestyle behaviours (such as the consumption of a healthy 
diet, being physically active, and smoking cessation) 
Women (n=119 799) Men (n=82 273) p value
Age, distribution, and disease history
Age 50·8 (9·9) 51·7 (10·0) p<0·0001
Living in rural communities (%) 51 706 (43·2%) 36 387 (44·2%) p<0·0001
Living in a high-income country (%) 9679 (8·1%) 8481 (10·3%) p<0·0001
Living in a middle-income country (%) 86 379 (72·1%) 55 711 (67·7%) p<0·0001
Living in a low-income country (%) 23 741 (19·8%) 18 081 (22·0%) p<0·0001
Previous cardiovascular disease (%) 6348 (5·3%) 5310 (6·5%) p<0·0001
Behavioural, psychosocial, and socioeconomic risk factors
Current smokers 11 839/118 647 (10·0%) 29 410/81 500 (36·1%) p<0·0001
High physical activity* 47 925/111 116(43·1%) 34 153/75 586 (45·2%) p<0·0001
Healthy diet† 30 400/90 245 (33·7%) 21 678/65 016 (33·3%) p=0·16
Ever consume alcohol 28 786/113 312 (25·4%) 39 191/77 716 (50·4%) p<0·0001
Probable depression‡ 16 351/112 540 (14·5%) 6111/76 644 (8·0%) p<0·0001
Low education§ 50 886/110 842 (45·9%) 28 779/77 627 (37·1%) p<0·0001
Physical measures and blood pressure, mean (SD) 
Body-mass index, kg/m² (n=190 800) 26·6 (5·6) 25·7 (4·9) p<0·0001
Waist circumference, cm (n=190 851) 84·3 (13·9) 89·0 (13·6) p<0·0001
Waist:hip ratio (n=182 985) 0·85 (0·08) 0·92 (0·08) p<0·0001
Systolic blood pressure, mm Hg 
(n=189 905)
129·9 (22·3) 133·5 (20·8) p<0·0001
Diastolic blood pressure, mm Hg 
(n=189 946)
80·9 (12·1) 82·7 (12·3) p<0·0001
Lipids and blood glucose, mean (SD)
Total cholesterol, mmol/L (n=142 428)¶ 5·5 (10·6) 5·2 (9·0) p<0·0001
Triglycerides, mmol/L (n=140 193)¶ 1·7 (5·3) 1·9 (4·6) p<0·0001
LDL-cholesterol, mmol/L 
(n=138 307)¶
3·2 (1·0) 3·1 (1·0) p<0·0001
HDL-cholesterol, mmol/L 
(n=139 631)¶
1·3 (0·4) 1·2 (0·3) p<0·0001
non-HDL-cholesterol, mmol/L 
(n=139 625)¶
3·8 (1·1) 3·7 (1·1) p<0·0001
ApoB, µmol/dL (n=20 940) 1·01 (0·3) 1·03 (0·3) p<0·0001
ApoA1, mol/dL (n=20 978) 1·6 (0·4) 1·4 (0·3) p<0·0001
ApoB:ApoA1 ratio (n=20 935) 0·68 (0·24) 0·75 (0·29) p<0·0001
Total cholesterol:HDL-cholesterol 
ratio (n=139 625)¶
4·2 (7·0) 4·6 (7·6) p<0·0001
Fasting blood glucose, mmol/L 
(n=141 250)
5·3 (1·8) 5·4 (1·9) p<0·0001
Data are n (%), n/N (%), or mean (SD). *High physical activity was defined as more than 3000 metabolic 
equivalents × min per week. †Healthy diet was defined as having an alternative healthy eating index score of more than 
31 (index scores range from 6 to 70). ‡Probable depression was defined as having five or more symptoms of 
depression; diagnosis was made on the basis of responses to Short-Form International Diagnostic Interview Schedule 
for Major Depressive Disorder. §Low education level was defined as no education, primary education only, or unknown 
education level. ¶Fasting blood samples used.
Table 1: Participant baseline characteristics
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separately in 11 658 participants with known cardiovascular 
disease (defined as those reporting a history of coronary 
heart disease including angina, myocardial infarction, 
coronary artery disease, and stroke) and those without 
(190 414 participants). Hyper tension control was assessed 
in participants with elevated systolic and diastolic blood 
pressures (>140/90 mm Hg). Use of glucose lowering 
agents was documented in participants with self­
reported diabetes. Smoking and its cessation, diet (using 
the modified Alternative Healthy Eating Index19), and 
physical activity (using the long­form International 
Physical Activity Questionnaire20) were documented at 
baseline data collection. Probable depression was 
defined as having five or more symptoms of depression, 
defined on the basis of responses to a Short­Form 
International Diagnostic Interview Schedule for Major 
Depressive Disorder. In participants with coronary 
artery disease, we recorded the proportion of participants 
who underwent percutaneous coronary intervention, 
coronary artery bypass grafting, and underwent cardiac 
diagnostic tests (echocardiograms, stress tests, and 
coronary angiograms).
Outcomes
There were two primary outcomes for this analysis. The 
first was major cardiovascular disease, a composite of 
cardiovascular deaths, myocardial infraction, stroke, 
heart failure, and other major cardiovascular events. The 
second primary outcome was all­cause death. Events 
from myocardial infarction, stroke, heart failure, and 
cardiovascular death are also reported as secondary 
outcomes. Detailed definitions of the events are available 
in the appendix (pp 13–22).
Statistical analysis
Continuous variables are presented as means with SDs. 
Categorical variables are presented as counts and propor­
tions. We used direct standardisation, according to the age 
and sex distribution of the PURE cohort, to calculate the 
age­standardised incidence rates (per 1000 person­years) 
for cardiovascular events and deaths. We used multilevel 
Cox proportional hazard models to obtain the hazard 
ratios (HRs) for major cardiovascular disease, myocardial 
infarction, stroke, heart failure, and all­cause death. In the 
multilevel structure, we considered individual participants 
nested in centres and considered centres as a random 
intercept effect. We mutually adjusted HRs for age, sex, 
location, and education. In separate analyses, we adjusted 
HRs for the INTERHEART risk score to assess the effect 
of risk factors on the outcomes; age was removed from 
these models because it is included in the INTERHEART 
risk score. We included the interaction terms of sex and 
country economic status and sex and geographical region. 
The proportionality of hazards was evaluated by visual 
inspection of the log–log survival plots. For all events we 
considered the first occurrence of the event of interest. 
We calculated 30­day and 30­day to 1­year case fatality 
rates following myocardial infarction, stroke, or heart 
failure event after adjustment for age. We modelled the 
associations between sex and use of preventive medicines, 
risk factor control, healthy lifestyle behaviours, cardiac 
tests, and revascularisations using multilevel mixed 
effects logistic regressions, adjusted for age, sex, education, 
and clustering for centres. The associations between sex 
and use of pre ventive medicines was further examined 
by additionally adjusting the odds­ratios (OR) for the 
INTERHEART risk score to control for cardio vascular 
disease risk. Differences in proportions between women 
and men were compared using two­sided χ² tests and 
differences between means using two­sided t tests. Given 
the multiplicity of comparisons, p values should be 
interpreted cautiously, except when they are very small (eg, 
p<0·0001) or consistent across several different related 
analyses.
Role of the funding source
External funders had no role in the study design, data 
collection, data analysis, data interpretation, writing of 
the report, or submitting of the report for publication. 
Three authors (MW­A, SR, and SY) had full access to the 
data and had final responsibility for the decision to 
submit for publication.
Results
Between Jan 6, 2005, and May 6, 2019, 202 072 partici pants 
(119 799 [59·3%] women and 82 273 [40·7%] men) 
aged 35–70 years were enrolled and followed up for 
measurement of risk factors associated with cardiovas­
cular disease, incident cardiovascular disease and all­
cause death. The median follow­up of the cohort was 
9·5 (IQR 8·5–10·9) years. Table 1 presents baseline 
Women (n=113 451) Men (n=76 963) p value
Overall 8·44 (8·43–8·46) 11·44 (11·41–11·46) p<0·0001
Economic status
High-income countries 11·44 (11·37–11·51) 14·38 (14·29–14·46) p<0·0001
Middle-income countries 8·62 (8·59–8·66) 11·84 (11·79–11·89) p<0·0001
Low-income countries 6·61 (6·57–6·64) 8·93 (8·88–8·97) p<0·0001
Region
North America and Europe 10·04 (10·00–10·09) 13·85 (13·78–13·92) p<0·0001
South America 9·60 (9·56–9·64) 11·58 (11·53–11·64) p<0·0001
Middle East 10·03 (9·96–10·10) 12·92 (12·83–13·01) p<0·0001
China 7·27 (7·24–7·30) 11·47 (11·42–11·52) p<0·0001
Southeast Asia 8·94 (8·89–8·99) 11·77 (11·69–11·84) p<0·0001
South Asia 6·76 (6·73–6·80) 9·18 (9·14–9·23) p<0·0001
Africa 8·02 (7·95–8·10) 8·73 (8·61–8·85) p<0·0001
Russia and Central Asia 7·26 (7·18–7·34) 10·40 (10·23–10·56) p<0·0001
All data are mean (95% CI). Participants with a history of cardiovascular diseases were excluded. Higher scores of the 
INTERHEART score indicate a higher risk factor burden. The INTERHEART risk score includes age, smoking, diabetes, 
blood pressure, family history of heart disease, waist:hip ratio, psychosocial factors, dietary factors, and physical activity. 
The estimated 10-year cardiovascular disease risk based on the Framingham risk score indicates that 10·5% of women 
and 37·3% of men are at high risk (≥20%) of developing the disease (appendix p 25).
Table 2: Mean non-laboratory INTERHEART risk score for women and men for the entire cohort and each 
economic and regional subgroup
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charac teristics of the study population. The mean age of 
women was 50·8 (SD 9·9) years compared with 51·7 (10) 
years for men. Less than half of the participants lived in a 
rural community (43·2% women and 44·2% men) and 
around 20% of both women and men included in the 
study were from a low­income country (table 1).
Fewer women were current smokers, had high levels of 
physical activity, or consumed alcohol, whereas probable 
depression and low education were more frequent in 
women than in men. Mean total cholesterol, LDL 
cholesterol, HDL cholesterol, non­HDL cholesterol, and 
ApoA1 concentrations were higher in women than men. 
By contrast, women had lower mean concentrations of 
triglycerides, ApoB, ratio of ApoB to ApoA1, and ratio of 
total cholesterol to HDL cholesterol. Waist circumference 
and waist:hip ratio were lower but mean BMI was higher 
in women than in men. Systolic and diastolic blood 
pressures and fasting blood glucose were also lower in 
women than in men. Fewer women reported a history of 
cardiovascular disease than men.
We assessed the risk factor burden in the subset 
of 190 414 participants who had not had a previous 
cardio vascular disease event (table 2). The mean 
INTERHEART risk score was lower in women than in 
men in the overall study (8·44 [95% CI 8·43–8·46] vs 
11·44 [11·41–11·46]; p<0·0001) and also within all groups 
of countries categorised by economic status and by 
geographical regions. In both women and men, the risk 
factor burden was highest in high­income countries, 
especially North America and Europe, and lowest in low­
income countries (table 2). The region with the lowest 
risk factor burden for men was Africa (8·73 [8·61–8·85]) 
and for women it was South Asia (6·76 [6·73–6·80]). 
Similar patterns were observed when examining the 
median INTERHEART risk score (appendix p 23).
The laboratory­based fasting cholesterol INTERHEART 
and the Framingham risk scores also showed similar 
patterns to the non­laboratory based INTERHEART risk 
factor analyses, with women having lower scores than 
men and a lower estimated 10­year risk of cardiovascular 
disease (appendix pp 24–25). A lower risk factor burden 
in women was also observed in participants with a history 
of cardiovascular disease, which remained even after the 
removal of smoking from the INTERHEART risk score 
Figure 1: Age-standardised incidence rates per 1000 person-years of major cardiovascular disease in those without a history of previous cardiovascular disease
Major cardiovascular disease includes cardiovascular death, myocardial infarction, stroke, heart failure, and other major cardiovascular disease events. Errors bars 
represent 95% CIs. Participants with a history of cardiovascular diseases are excluded. Interaction between economic status and sex p<0·0001; interaction between 
geographic region and sex p<0·0001. IR=age standardised incidence rates per 1000 person-years. aHR=adjusted hazard ratio. HIC=high-income country. 
MIC=middle-income country. LIC=low-income country. *Hazard ratios are adjusted for location, education, INTERHEART risk score, and a random intercept for 
centre. The INTERHEART risk score includes age, smoking, diabetes, blood pressure, family history of heart disease, waist:hip ratio, psychosocial factors, dietary 
factors, and physical activity.
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(appendix pp 26–27). Women had a lower risk factor 
burden than men even after modifying the scoring 
system so that women and men were assigned the same 
number of points for age (appendix p 28).
8332 participants without history of cardiovas­
cular disease had a major cardiovascular disease event 
during follow­up (3905 [47%] women and 4427 [53%] 
men), and 10 244 participants died from any cause 
(4570 [45%] women and 5674 [55%] men). Women had 
lower inci dence of age­standardised major cardiovascular 
disease (4·1 [95% CI 4·0–4·2] per 1000 person­years) 
than did men (6·4 [6·2–6·6]). Lower incidence rates of 
major cardiovascular disease in women compared to 
men were observed across all economic and geographical 
regions, except Africa where there were relatively few 
events (figure 1). Overall, the risk of a major cardiovascular 
disease event was 38% lower in women without 
adjustment for the INTERHEART risk score (adjusted 
HR 0·62 [95% CI 0·60–0·65]), and this risk was only 
partly attenuated after further adjusting for the 
Figure 2: Age-standardised incidence rates per 1000 person-years of myocardial infarction, stroke, heart failure, and cardiovascular death in those without 
previous cardiovascular disease
Errors bars represent 95% CIs. Of note, 385 other major cardiovascular events (261 in women and 124 in men) included in major cardiovascular are not presented 
above. Data are not presented by geographical region because the numbers of events of myocardial infarction, stroke, and heart failure are substantially reduced 
resulting in unstable estimates. Interaction between country economic status and sex p=0·0001 for myocardial infarction events; p=0·0001 for stroke events; 
p=0·3006 for heart failure events. Interaction between country economic status and sex p=0·0001 for cardiovascular deaths. IR=age standardised incidence rates per 
1000 person-years. aHR=adjusted hazard ratio. HIC=high-income country. MIC=middle-income country. LIC=low-income country. *Hazard ratios are adjusted for 
location, education, INTERHEART risk score, and a random intercept for centre ID. The INTERHEART risk score includes age, smoking, diabetes, blood pressure, family 
history of heart disease, waist:hip ratio, psychosocial factors, dietary factors, and physical activity.
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INTERHEART risk score (0·75 [0·72–0·79]). The risk of 
each component of major cardiovascular disease was 
also lower in women than men (figure 2). Overall, 
women had a 41% lower risk of myocardial infarction 
(0·59 [0·55–0·63]), a 14% lower risk of stroke (0·86 
[95% CI 0·80–0·92]), a 14% lower risk of heart failure 
(0·86 [0·75–0·99]), and a 41% lower risk of cardiovascular 
death (0·59 [0·55–0·64]) compared with men.
Age­standardised all­cause deaths per 1000 person­years 
was also lower in women (4·5 [95% CI 4·4–4·7]) than in 
men (7·4 [7·2–7·7]). The smallest difference between all­
cause death in men and women was in high­income 
countries (incidence rate difference 0·8) and the largest 
difference was reported in low­income countries (inci­
dence rate difference 4·4), around five­times more than 
that seen in HICs (figure 3). Overall, the risk of all­cause 
death was 44% lower in women without adjustment 
for the INTERHEART risk score (adjusted HR 0·56 
[95% CI 0·54–0·59]), and 38% lower after adjustment 
(0·62 [0·62–0·65]).
Overall, the 30­day case fatality rates after a myocardial 
infarction, stroke, or heart failure event were 22% for 
women and 28% in men (p<0·0001; figure 4). Similar 
30­day case fatality rates were observed for women and 
men in high­income countries (5% in women and 7% in 
men; p=0·79). The difference in 30­day case fatality 
rates between women and men were more marked in 
middle­income countries (18% in women vs 24% in men; 
p<0·0001) and low­income countries (38% in women vs 
44% in men; p=0·0058; figure 4). Examining the risk of 
cardiovascular death over the entire follow­up duration 
after a diagnosis of myocardial infarction, stroke, or heart 
failure did not alter our conclusions (appendix p 30). 
Lower 1­year case­fatality rates in women compared 
with men were also observed for each component of 
cardiovascular disease (ie, myocardial infarction, stroke, 
and heart failure), but these differences were not 
separately statistically significant (appendix p 31).
Of the 190 414 participants without cardiovascular 
disease at baseline, use of antiplatelets, β blockers, ACE 
inhibitors or angiotensin receptor blockers, diuretics, 
calcium­chan nel blockers, statins, and glucose lowering 
agents was significantly higher in women after adjust ment 
for the participants’ sociodemographic charac teristics 
and the INTERHEART risk score, but the differences in 
crude proportions were small (table 3). Women were also 
Figure 3: Age-standardised incidence rates per 1000 person-years of all-cause death in those without previous cardiovascular disease
Participants with a history of cardiovascular diseases are excluded. Interaction between sex and country economic status p<0·0001; Interaction between sex and 
geographic region p<0·0001. Errors bars represent 95% CIs. IR=age standardised incidence rates per 1000 person-years. aHR=adjusted hazard ratio. HIC=high-income 
country. MIC=middle-income country. LIC=low-income country. *Hazard ratios adjusted for location, education, INTERHEART risk score, and a random intercept for 
centre. The INTERHEART risk score includes age, smoking, diabetes, blood pressure, family history of heart disease, waist:hip ratio, psychosocial factors, dietary 
factors, and physical activity.
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significantly more likely to have their hypertension 
controlled, and to quit smoking. However, the differences 
between women and men for consuming a healthy diet 
and physical activity was modest. By contrast, of the 
11 658 partici pants with previous cardiovascular disease 
women were significantly less likely to use antiplatelet 
drugs, ACE inhibitors or angiotensin receptor blockers, 
any blood­pressure lowering medicine, or statins, after 
adjustment for participants’ sociodemographic charac­
teristics and the INTERHEART risk score. However, 
women with a history of cardiovascular disease were more 
likely to use diuretics, calcium­channel blockers, and 
hypoglycaemic agents, and these participants were also 
more likely to have their hypertension controlled and be 
physically active (table 3).
Women were less likely to have echocardiograms, 
stress tests, coronary angiograms, or revascularisation 
procedures compared with men. These patterns were 
observed for countries at all economic levels (table 4). 
Despite the lower number of cardiac tests and revas­
cularisation procedures in women, the risk of a 
subsequent major cardiovascular disease event was lower 
in women than men with a history of coronary disease 
(figure 5). This pattern was observed in low­income 
and middle­income countries but not in high­income 
countries, where the risk of subsequent cardiovascular 
disease was similar between women and men.
Discussion
Several key conclusions can be drawn from our study. 
First, overall burden of cardiovascular disease risk factors 
was lower in women than in men, in all groups of 
countries by economic status, in all geographical regions, 
and in participants with and without a history of 
cardiovascular disease. Second, women without a history 
of cardiovascular disease were more likely to use 
preventive medicines, have controlled hypertension, and 
to have quit smoking. However, the absolute differences 
in these crude proportions were small. Moreover, the risk 
of major cardiovascular disease and all­cause death in 
those without previous cardiovascular disease were also 
lower in women, even after adjustment for participants’ 
risk factor burden. Third, in participants with previous 
cardiovascular disease, secondary prevention medi­
cines, cardiac tests, and revascularisation pro cedures 
were less frequently used in women than men. Despite 
these findings, women with a history of cardiovascular 
disease had a lower risk of recurrent major cardiovascular 
disease event. The 30­day case fatality rates from an 
incident major cardiovascular disease event was also 
lower in women. Finally, although the differences in 
cardiovascular disease incidence and case­fatality rates 
between women and men were observed in countries at 
all economic levels, these differences were modest in 
high­income countries and considerably greater in other 
countries.
A lower risk factor burden in women than in men, 
which was observed with both the INTERHEART and 
Framingham scores, is consistent with previous studies. 
For instance, data from the UK Biobank in a sample of 
471 998 people without a history of cardiovascular disease 
reported that fewer women smoked and fewer had 
hypertension, diabetes, or obesity compared with men.21 
Data from the Framingham Offspring cohort reported 
that the 30­year risk of cardiovascular disease was 
substantially lower in women (7·6%) than men (18·3%).22 
A meta­analysis of 18 cohorts involving 250 000 women 
and men from the USA reported lower calculated 
lifetime risk of death from cardiovascular disease in 
women than men.23 PURE extends these observations to 
many countries in different regions of the world. The 
consistently lower risk factor burden in women compared 
with men in diverse settings suggests that women might 
be inherently at lower risk for cardiovascular disease 
than men. The reasons for this remain unclear, although, 
differences in oestrogen concentration are commonly 
thought to be the reason for women’s cardioprotection. 
However, three large clinical trials of the effects 
oestrogens did not show benefit, and the role of 
oestrogens in protecting women from cardiovascular 
disease remains unproven.24 Our data suggest that a 
higher prevalence of primary prevention strategies and 
healthy lifestyle behaviours observed in women is likely 
to contribute to their lower cardiovascular disease risk.
In participants without a history of cardiovascular 
disease, women had a lower risk of incident cardiovascular 
disease and all­cause deaths even after adjustment for the 
INTERHEART risk score. Adjusting for the individual 
Figure 4: Case fatality rates after an incident myocardial infarction, stroke, or heart failure event in women 
and men by country economic status
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components of the INTERHEART risk score instead of 
the overall INTERHEART risk score did not alter this 
conclu sion (appendix pp 32–33). Although data that 
include large cohorts from low­income and middle­income 
countries are few in number, previous studies with 
predominantly North American and European populations 
have also reported lower cardiovascular disease incidence 
and deaths in women.5,23
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Quit smoking among ever smokers 9644/20 880 
(46·2%)
14 606/42 541 
(34·2%)





Healthy eating 28 765/86 132 
(33·4%)









Physically active§ 45 482/105 042 
(43·3%)
32 259/70 546 
(45·7%)





OR=odds ratio. ACE=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. *OR adjusted for age, education, urban versus rural location. †OR adjusted for age, education, urban versus rural 
location, and INTERHEART risk score. ‡Blood-pressure lowering medicines include any of β blockers, ACE inhibitors, ARBs, diuretics, calcium-channel blockers, and alpha-antagonist. §High physical activity was 
defined as having performed more than 3000 metabolic equivalent × min per week.
Table 3: Use of preventive medicines, risk factor control, and healthy lifestyle behaviours in participants without and with a history of cardiovascular disease
Cardiac tests Revascularisation procedures (PCI or 
CABG)


































































































































PCI=percutaneous coronary intervention. CABG=coronary artery bypass grafting. OR=odds ratio. *OR adjusted for age, education, urban versus rural location, and random intercept for centre.
Table 4: Number of participants who received cardiac tests and coronary revascularisation procedures in women and men with coronary artery disease overall and by economic status
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Unlike primary prevention, we observed that in partici­
pants with existing cardiovascular disease, secondary 
prevention drugs, diagnostic tests, and revascularisation 
procedures were less frequent in women than in men, 
which is consistent with previous studies.10 Nevertheless, 
women had lower risks of recurrent cardiovascular 
disease events and 30­day deaths after a new cardio­
vascular disease event compared with men. Why women 
with established cardiovascular disease are treated less 
frequently while the opposite is seen in primary 
prevention is not clear. Participants with existing cardio­
vascular disease were approximately 7 years older than 
those without a history of cardiovascular disease 
(appendix pp 34–35), and it is possible that in those 
with cardio vascular disease, women are more likely 
to experience side­effects from antiplatelet drugs, 
thrombolytics, or statins and discontinue this medication 
compared with men.25–27 Appropriate dosing of secondary 
prevention medicines might also vary for women and 
men. For example, Santema and colleagues28 reported 
that women with heart failure with reduced ejection 
fraction required lower doses of guideline recommended 
therapies pos sibly because of their lower bodyweight 
and height compared with men.
Studies have also suggested that women more 
frequently present with atypical symptoms than do 
men,29 which might contribute to delays in diagnosis and 
provision of subsequent care. However, reports of women 
presenting with atypical symptoms more frequently than 
men are highly variable largely because of the absence of 
standardised definitions and methods for collecting data 
on presenting symptoms. Following an acute event, 
women might also present to the health­care system later 
than men. The International Survey of Acute Coronary 
Syndromes in Transitional Countries registry reported 
that women with ST­elevation myocardial infarction 
had an approximately 30 min longer symptom onset 
to hospital presentation time than men.30 However, 
there were no differences in door­to­balloon time or 
door­to­needle time between women and men. The lower 
number of revascularisation procedures observed in 
women with established coronary artery disease might 
partly be explained by a lower burden of atherosclerosis 
in women. Previous studies have reported that women 
are more likely than men to have non­obstructive 
coronary artery disease but, irrespective of age, men have 
significantly more obstructive coronary disease and 
multivessel disease than women across the spectrum of 
acute coronary syndrome.31–35 Furthermore, data from 
previous studies show that although revascularisation is 
more common in men than in women with mild disease, 
sex differences in revascularisation are not observed in 
those with advanced disease.31,34–36 We were unable to 
stratify revascularisation rate by disease severity at time of 
presentation, but women with previous cardiovascular 
disease had lower INTERHEART risk scores than did 
men with previous cardiovascular disease (appendix 
p 26). The lower INTERHEART risk scores might also 
contribute to less intensive investigation of women with 
previous cardio vascular disease. Given the older age at 
which women with coronary artery disease present 
compared with men, their perioperative risks from 
coronary artery bypass grafting surgery or percutaneous 
coronary intervention could be higher.37 This might 
more often lead to a reluctance from physicians to 
perform some procedures in women than in men. Future 
research should therefore investigate whether women 
and men differ in their suitability and contraindications 
for certain treatments and procedures. Whether women 
and men differ in their priorities and preferences for 
secondary prevention medicines or revascularisation 
therapies is unknown.
The contrasting patterns in the differences between 
women and men in primary prevention compared 
Figure 5: Age-standardised incidence rates per 1000 person-year of major cardiovascular disease in those with a history of coronary artery disease
Major cardiovascular disease includes cardiovascular death, myocardial infarction, stroke, heart failure, and other major cardiovascular disease events. Errors bars 
represent 95% CIs. Interaction between sex and country economic status p=0·0018. IR=age standardised incidence rates per 1000 person-years. aHR=adjusted hazard 
ratio. HIC=high-income country. MIC=middle-income country. LIC=low-income country. *Hazard ratios adjusted for location, education, INTERHEART risk score, 
and a random intercept for centre. The INTERHEART risk score includes age, smoking, diabetes, blood pressure, family history of heart disease, waist:hip ratio, 
psychosocial factors, dietary factors, and physical activity.
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with secondary prevention are not readily explained. To 
date, most studies have acutely focused on treatment 
differences in women compared with men following a 
cardiovascular disease event and often conclude that 
some combination of implicit and explicit biases have 
resulted in women being undertreated.38,39 However, 
both the lower incidence of cardiovascular disease and 
death in women than in men in those with and without 
a history of cardiovascular disease in our study suggests 
that the overall approaches to the prevention of 
cardiovascular disease do not lead to worse outcomes in 
women. Our data indicate that women with coronary 
artery disease have better prognosis despite less 
aggressive treatments. These findings suggest that 
there might be factors, other than a bias, that favour 
more vigorous management of cardiovascular disease 
in men.
Our data do not conflict with the literature. A systematic 
review of studies reporting sex differences in long­term 
prognosis after an acute myocardial infarction found that 
most studies reported similar or lower death rates for 
women compared with men, after adjustment for age 
and other characteristics.40 Vaccarino and colleagues41 
came to a similar conclusion for early death (ie, in­
hospital or during the first 4–6 weeks). In their review of 
studies published between 1966 and 1994, adjusting for 
age only resulted in no significant differences in deaths 
between women and men in nine of the 11 studies 
reviewed. In six studies that adjusted for age and other 
covariates, only one reported significantly more deaths in 
women than men. We also undertook a comprehensive 
review of the literature (appendix pp 34–35). A few 
studies suggested more deaths in women, particularly at 
younger ages in women with ST­elevation myocardial 
infarction,42,43 but most large studies observed that 
cardiovascular disease outcomes were not higher in 
women compared with men. Interestingly, some of the 
studies reporting more deaths in young women 
with ST­elevation myocardial infarction found that the 
pattern persisted even in the subset of women receiving 
revascularisation procedures.42,43
Of note, for both women and men the incidence of a 
recurrent cardiovascular disease event and 30­day case 
fatality rates were greatest in low­income and middle­
income countries, with little difference in high­income 
countries. A number of observational studies in low­
income and middle­income countries have highlighted 
inadequate access to quality health­care services,44 poor 
health literacy, and suboptimal use of medicines to 
control blood pressure,45 cholesterol,46 and glucose,47 
which might explain some of the excess burden of 
cardiovascular disease in these countries and support 
efforts to improve the management of cardiovascular 
disease for both women and men.
Our study has a few potential limitations. First, it is 
possible that the risk scores underestimate cardiovascular 
disease risk in women. The INTERHEART risk score 
does not include female­specific risk factors, such as 
gestational diabetes, history of pre­eclampsia, or preg­
nancy induced hypertension because information on 
these factors were not collected in PURE. The inclusion 
of these factors to improve cardiovascular disease risk 
prediction in women has not been previously evaluated.48 
Moreover, a systematic review of risk prediction models 
in women in the general population concluded that 
established sex independent cardio vascular disease risk 
predictors (ie, age, blood pressure, and smoking) made 
the greatest contribution to model performance.48 
Second, although we accounted for differences in risk 
factor burden when examining use of primary and 
secondary prevention medicines, we were unable to 
account for differences in eligibility for or contraindi­
cations to specific medicines. The remaining variations 
in treatment use could be due to unmeasured factors, 
such as differences in treatment preferences. Third, 
although our study is the first to explore differences 
between women and men in several geographical 
regions, the number of cardiovascular disease events in 
Africa was relatively low (ie, <400 people with incident 
cardiovascular disease); therefore, conclusions related to 
the burden of cardiovascular disease in women compared 
with men in Africa should be interpreted with caution. 
However, the incidence of cardiovascular disease and 
all­cause death were higher in men than in women in 
Africa, suggesting that the general pattern of higher 
cardiovascular disease death in men holds true for 
all regions of the world. Fourth, the detection of 
cardiovascular events in low­income and middle­income 
countries might be less complete if access to hospitals 
and diagnostic facilities were poorer for the participants 
in these countries. If this were the case, we would expect 
even higher rates of cardiovascular disease in both 
women and men in poorer countries, but this should 
not affect women and men differentially. Fifth, we are 
unable to discriminate between ST­elevation myocardial 
infarction from a non­ST­elevation myo cardial infarction 
and outcomes in women compared with men could vary 
according to the type of acute coronary syndrome. The 
existing evidence is mixed; although many studies 
suggest no sex differences in deaths in both patients with 
ST­elevation myocardial infarction and non­ST­elevation 
myocardial infarction,33,49 some report worse outcomes 
in women with ST­elevation myocardial infarction 
compared with men, especially at younger ages.42,43 Sixth, 
relatively few individuals developed incident heart failure 
(830 [0·5%] individuals). Therefore, conclusions related 
to differences between women and men in the incidence 
and case fatality rates of heart failure by country economic 
status should be interpreted with caution. Our findings, 
of lower incidence of heart failure in women than in men 
but similar death rates between the two groups as a result 
of heart failure, are generally consistent with previous 
studies.50 With extended follow­up and a planned 
expansion of the PURE study, we expect to be able to 
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provide more robust results on heart failure in a few 
years. Similarly, case fatality rates beyond 30­days but 
less than 1­year and the 30­day case fatality rates in high­
income countries were low. Therefore, conclusions 
related to the patterns by sex, especially during the 30­day 
to 1­year period, should be interpreted with caution.
In conclusion, treatments for cardiovascular disease 
were more common in women than men who do not 
have known cardiovascular disease (primary prevention); 
however, use of secondary prevention medications, 
diagnostic tests, and revascularisation procedures were 
less frequent in women. Despite these findings, 
consistently better outcomes were observed in women 
than in men in those without and in those with 
cardiovascular disease. Larger gaps were observed in 
disease management and worse outcomes in both women 
and men in poorer countries than in richer countries. 
Therefore, greater efforts to improve prevention and 
management of cardiovascular disease in both women 
and men worldwide, but especially in low­income and 
middle­income countries, are warranted.
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